COMMUNIQUÉS West-GlobeNewswire

HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration

15/04/2025 - 11:00

Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing and completion of a [...]

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

15/04/2025 - 11:00

MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi , CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Montalcini Global [...]

Best Diabetes Supplement of 2025: Learn How GlucoRedi Sets a New Benchmark in Wellness Industry

15/04/2025 - 11:39

Nampa, April 15, 2025 (GLOBE NEWSWIRE) -- Best Diabetes Supplement of 2025: Learn How GlucoRedi Sets a New Benchmark in Wellness Industry Glucoredi diabetes supplement Content Promoted By Branding EX Solution pvt ltd ( [...]

Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

15/04/2025 - 12:00

LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, [...]

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

15/04/2025 - 12:22

Company Announcement Net sales of DARZALEX ® in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc [...]

Native Path Native Hydrate Reviews [Urgent Update]: Don’t Buy Until You Read This

15/04/2025 - 12:28

Native Hydrate by Native Path Reviews Woodhaven, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- What if the key to better hydration and muscle recovery wasn’t in sugary sports drinks but in a clean, science-backed formula? [...]

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

15/04/2025 - 12:30

HUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology [...]

Conavi Medical Corp. Announces Pricing of Public Offering of Common Shares

15/04/2025 - 13:00

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES A&R PROSPECTUS AND FINAL PROSPECTUS ACCESSIBLE ON SEDAR+ TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. ( [...]

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

15/04/2025 - 13:00

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates superior potency of [...]

Remix Therapeutics Appoints Linda C. Bain to Board of Directors

15/04/2025 - 13:00

WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers [...]

Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

15/04/2025 - 13:00

New clinical data from the SYMON-I study to evaluate IL-6 in sepsis patients to be presented. ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced acceptance of an [...]

Vistin Pharma ASA: Invitation to Q1 2025 conference call

15/04/2025 - 13:00

Oslo, Norway, 15 April 2025 Vistin Pharma ASA (VISTN) will release its first quarter results on Friday 25th of April 2025. Vistin Pharma will host a conference call for all shareholders and interested parties at the [...]

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

15/04/2025 - 13:00

Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population Additional [...]

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

15/04/2025 - 07:30

Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through [...]

CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Obesity and Overweight Conditions

15/04/2025 - 07:37

The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemes The trial is expected to enroll 250 patients to receive treatment over 36 weeks BERKELEY HEIGHTS [...]

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

15/04/2025 - 08:00

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The agreement focuses on further research and development of a novel, first-in- [...]

Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S

15/04/2025 - 08:15

April 15, 2025 Announcement no. 11 Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S Copenhagen, Denmark, April 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S [...]

Correction: Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S

15/04/2025 - 08:31

April 15, 2025 Announcement no. 11 Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S Copenhagen, Denmark, April 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S [...]

Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics

15/04/2025 - 09:00

MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeutics Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and sales [...]